The Motley Fool: Novo Nordisk has growth potential and dividend yield

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

Novo Nordisk A/S (NVO)’s Top Investor Decides to Take Control of its Board, Reports Reuters

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk ...

Novo Nordisk chair, board members to quit after dispute with top shareholder

The chairman of Novo Nordisk and six other independent board members quit on Tuesday after a dispute with the company's ...

Long-time Novo Nordisk bull tapped to lead Wegovy maker’s IR division

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...
TipRanks on MSN

Novo Nordisk’s Wegovy Pregnancy Study: Safety Insights and Market Impact

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled ‘Wegovy® ...
Healio

Novo Nordisk drops Wegovy collaboration with Hims & Hers, alleges unsafe tactics

Please provide your email address to receive an email when new articles are posted on . Novo Nordisk alleges that Hims & Hers Health has engaged in illegal drug compounding and deceptive marketing ...

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be ...

Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting

Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver ...